References

1. ^World Health Organization (2011)."International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 105"(PDF).WHO Drug Information.25 (2).^{[dead link]}
2. ^Statement On A Nonproprietary Name Adopted By The USAN Council - Pateclizumab,American Medical Association.
3. ^Kennedy WP, Simon JA, Offutt C, Horn P, Herman A, Townsend MJ, Tang MT, Grogan JL, Hsieh F, Davis JC (October 2014)."Efficacy and safety of pateclizumab (anti-lymphotoxin-α) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study)".Arthritis Res. Ther.16 (5): 467.doi:10.1186/s13075-014-0467-3.PMC 4243296.PMID 25359150.
4. ^Emu B, Luca D, Offutt C, Grogan JL, Rojkovich B, Williams MB, Tang MT, Xiao J, Lee JH, Davis JC (January 2012)."Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin α: results of a phase I randomized, placebo-controlled trial".Arthritis Res. Ther.14 (1): R6.doi:10.1186/ar3554.PMC 3392792.PMID 22225620.
5. ^Wang H, Schuetz C, Arima A, Chihaya Y, Weinbauer GF, Habermann G, Xiao J, Woods C, Grogan J, Gelzleichter T, Cain G (August 2016). "Assessment of placental transfer and the effect on embryo-fetal development of a humanized monoclonal antibody targeting lymphotoxin-alpha in non-human primates".Reprod. Toxicol.63:82–95.doi:10.1016/j.reprotox.2016.05.014.PMID 27211603.S2CID 41454952.
6. ^Hirose T, Fukuma Y, Takeshita A, Nishida K (June 2018). "The role of lymphotoxin-α in rheumatoid arthritis".Inflamm. Res.67 (6):495–501.doi:10.1007/s00011-018-1139-6.PMID 29541795.S2CID 3910200.